A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Conatumumab (Primary) ; Ganitumab
- Indications Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; NantCell
- 01 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Jan 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Sep 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.